Stocks · News reference
Alnylam Pharmaceuticals announced an update to its Phase 3 TRITON-CM study of nucresiran, expanding the target enrollment to approximately 2,250 patients.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Alnylam Pharmaceuticals announced its third-quarter 2026 financial results, reporting revenue of $1.46 billion and adjusted EPS of $16.26, while reaffirming its full-year 2026 financial outlook.
Filed: 2026-10-29 AccNo: 0001178670-26-000074 Size: 513 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Alnylam Pharmaceuticals reported positive initial Phase 1b clinical trial results for brezosiran (ALN-HTT02), demonstrating deep and durable reductions of mutant huntingtin protein in patients with Huntington's disease.